Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06500884 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
A Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06500884 is a Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 130 participants, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06500884, a Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
Conditions Studied
Interventions
- DRUG Talquetamab
- DRUG Prophylaxis A
- DRUG Prophylaxis B
- DRUG Prophylaxis C
Study Locations (20)
Other
- Hospitais Integrados da Gavea SA DF Star - Brasília
- Fundacao Universidade de Caxias do Sul - Caxias do Sul
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer - Curitiba
- Instituto D Or de Pesquisa e Ensino - Salvador
- Clinica Medica Sao Germano S/S LTDA - São Paulo
- Instituto D Or de Pesquisa e Ensino IDOR - São Paulo
- VUMC Amsterdam - Amsterdam
- Albert Schweitzer Ziekenhuis - Dordrecht
- Erasmus MC - Rotterdam
- Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center - San Juan
- Seoul National University Hospital - Seoul
New York
- Icahn School of Medicine at Mt. Sinai - New York
- University of Rochester Medical Center - Rochester
California
- University of California San Francisco - San Francisco
Colorado
- Colorado Blood Cancer Institute - Denver
Connecticut
- Yale University School Of Medicine - New Haven
North Carolina
- Duke University Medical Center - Durham
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Virginia
- Virginia Commonwealth University - Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06500884
The ClinicalTrials.gov registry entry for NCT06500884 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Talquetamab is the first listed.
NCT06500884 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT06500884 about?
NCT06500884 is a clinical study titled "A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity". The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste...
What is the current status of trial NCT06500884?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2024-08-26. Estimated completion is 2029-04-30.
What conditions does trial NCT06500884 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma.
What interventions are being tested in trial NCT06500884?
The interventions under investigation include: Talquetamab (DRUG), Prophylaxis A (DRUG), Prophylaxis B (DRUG), Prophylaxis C (DRUG).
Who is sponsoring clinical trial NCT06500884?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06500884 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
RECRUITING · Phase 2
-
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.